Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 USD | -1.83% | +2.88% | +13.83% |
Financials (USD)
Sales 2024 * | 200K | Sales 2025 * | 200K | Capitalization | 29.05M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -23M | EV / Sales 2024 * | 145 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 145 x |
P/E ratio 2024 * |
-2.06
x | P/E ratio 2025 * |
-3.42
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.5% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | -1.83% | ||
1 week | +2.88% | ||
Current month | +4.90% | ||
1 month | -19.79% | ||
3 months | -6.47% | ||
6 months | +33.75% | ||
Current year | +13.83% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 5.35 | -1.83% | 2,249 |
24-05-02 | 5.45 | +3.81% | 2,608 |
24-05-01 | 5.25 | +2.94% | 2,971 |
24-04-30 | 5.1 | +0.31% | 14,870 |
24-04-29 | 5.084 | -2.23% | 2,551 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.83% | 29.05M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- APRE Stock